Sun Pharma's USD11.75bn Acquisition of Organon: Market Analysis
Decision brief
Answer first · skim in under a minute
Sun Pharma's recent acquisition of Organon for USD11.75bn marks a significant shift in the pharmaceutical landscape. This article analyzes the market implications and investment opportunities.
Sun Pharma signed a definitive agreement to acquire Organon for $14.00 per share in an all-cash deal valuing the company at an $11.75 billion enterprise value, with closing targeted for early 2027 subject to regulatory and stockholder approvals.
Contents11 sections
Key Takeaways
- April 26, 2026 announcement: Sun Pharma will acquire all outstanding Organon shares for $14.00 cash per share.
- Enterprise valuation is stated at $11.75 billion; boards of both companies approved the merger structure.
- Organon reported $6.2 billion revenue and $1.9 billion Adjusted EBITDA for the year ended Dec. 31, 2025.
- Closing is expected in early 2027 after required regulatory clearances and Organon stockholder approval.
What are the confirmed Sun Pharma-Organon deal terms?
Organon SEC exhibit materials and the joint announcement state Sun Pharma will acquire 100% of Organon outstanding shares for $14.00 per share in cash at an enterprise valuation of $11.75 billion. See the SEC EX-99.1 release.
A parallel Business Wire release restates the same cash consideration, EV, and early-2027 close target.
How is the merger structured and financed?
The DEFA14A merger disclosure describes a merger of Organon with a Sun Pharma subsidiary, with Organon surviving as a wholly owned subsidiary.
Sun Pharma plans to fund the acquisition with available cash and committed bank financing. Proxy materials also reference bridge financing capacity tied to closing needs.
What financial baseline does Organon bring?
- FY2025 revenue: $6.2 billion
- FY2025 Adjusted EBITDA: $1.9 billion
- Debt: $8.6 billion; cash: $574 million (year-end 2025 figures in the announcement)
- Recent product divestiture upfront: $440 million
Investor decks filed with the SEC also cite a large premium to Organon closing price on April 9, 2026, and combined-scale ambitions after close.
What market implications follow for APAC and women's health?
Organon portfolios in women's health, established brands, and biosimilars would expand Sun Pharma geographic and therapeutic reach if the deal closes as planned.
Competitors in women's health and biosimilars should model a larger, cash-funded Indian-listed buyer with multi-region commercial infrastructure rather than a standalone Organon trajectory.
Which approvals still gate the Organon acquisition?
Closing remains subject to customary conditions, including required regulatory approvals and Organon stockholder approval.
Until those conditions clear, teams should treat synergy, ranking, and combined-revenue claims as forward-looking statements rather than completed facts.
What remains unproven before closing?
Antitrust outcomes, final financing mix, integration costs, and post-close use metrics are not settled in the announcement package.
Any claim that the deal already closed in 2023 or earlier is inconsistent with the April 2026 definitive-agreement primaries and is omitted.
What should APAC investors watch before the Organon close?
Model early-2027 closing risk under antitrust review rather than treating the April 2026 signing as a completed merger.
Stress-test Sun Pharma funding plans that mix cash and bank commitments, including any bridge facility size disclosed in proxy materials.
Map Organon women health and biosimilar brands against Sun Pharma existing franchises to find overlap versus white-space markets across 150 stated country footprints in investor slides.
Keep debt and cash baselines in view: $8.6 billion debt and $574 million cash at year-end 2025, plus the $440 million divestiture inflow noted in the announcement.
Related NovaPharma coverage
- NMPA and China FDA pathways 2026
- Hengrui Kailera ribupatide ADA 2026 data
- NMPA drug approvals 2025 record
Frequently Asked Questions
How much is Sun Pharma paying for Organon?
Sun Pharma agreed to pay $14.00 per share in cash, corresponding to an enterprise valuation of $11.75 billion in the companies joint announcement.
When is the Organon acquisition expected to close?
The parties expect closing in early 2027, subject to regulatory approvals and Organon stockholder approval among other customary conditions.
Is the Sun Pharma-Organon deal already closed?
No. As of the April 2026 definitive agreement disclosures, the transaction remains pending required approvals and has not closed.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
